Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)
The DOI matches its Crossref record; 100 of the 120 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The identification by Abifadel et al. in 2003 of the first mutations of PCSK9 was the major breakthrough in the cholesterol field that led to a new therapeutic target. This discovery paved the way to new lipid lowering drugs reducing LDL-cholesterol levels through the inhibition of PCSK9. Two anti-PCSK9 monoclonal antibodies have received FDA and EMA approvals: Alirocumab and Evolocumab. Areas covered: This article reviews the different strategies that are pursued to modulate the functional activity of PCSK9 for lowering LDL-cholesterol levels. It also provides a brief overview of the patents related to PCSK9 from 2011 until the end of 2015. This review is addressed to researchers from academia and pharmaceutical companies who are engaged in PCSK9 research/cholesterol regulation. Readers will gain an up-to-date overview of the different strategies that have been investigated to reduce PCSK9, focusing on anti-PCSK9 monoclonal antibodies and the related clinical trials. Expert opinion: Anti-PCSK9 antibodies are a new class of lipid lowering drugs with promising results in reducing LDL-cholesterol. Long-term ongoing studies investigating on a large scale the efficacy and safety of the anti-PCSK9 antibodies and their cardiovascular outcomes are eagerly awaited.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL-C level was −62%; the treatment effect remained consistent over a period of 78 weeks [83].”
MethodLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationRaal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61399-4 · Cited by 756
Raal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720 · cited 1×
“5% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe [100].”
BackgroundDecreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 632
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596 · cited 1×
“Regulation of endogenous and exogenous PCSK9 has been well documented and reviewed by our team elsewhere [5,19,24].”
BackgroundSelf-citationStein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 588
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., & Prat, A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000134621.14315.43 · Cited by 570
Self-citationKastelein, J. J. P., Ginsberg, H. N., Langslet, G., Hovingh, G. K., Ceska, R., Dufour, R., Blom, D., Civeira, F., Krempf, M., Lorenzato, C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv370 · Cited by 533
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.019 · Cited by 526
McKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Raal, F., Scott, R., Somaratne, R., Bridges, I., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 508
Robinson, J. G., Nedergaard, B. S., Rogers, W. J., Fialkow, J., Neutel, J. M., Ramstad, D., Somaratne, R., Legg, J. C., Nelson, P., Scott, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.4030 · Cited by 496
Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470
Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
Giugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 428
Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., Tremblay, M., Jacques, H., Jin, W., Davignon, J., et al. (2008) · Hepatology · doi:10.1002/hep.22354 · Cited by 404
Self-citationNavarese, E. P., Kołodziejczak, M., Schulze, V., Gurbel, P. A., Tantry, U., Lin, Y., Brockmeyer, M., Kandzari, D. E., Kubica, J. M., D'Agostino, R. B., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2957 · Cited by 404
Cannon, C. P., Cariou, B., Blom, D., McKenney, J. M., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv028 · Cited by 402
Molecular basis for LDL receptor recognition by PCSK9
Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., & Deisenhofer, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712064105 · Cited by 389
Koren, M. J., Scott, R., Kim, J. B., Knusel, B., Liu, T., Lei, L., Bolognese, M., & Wasserman, S. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61771-1 · Cited by 366
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Hooper, A. J., Marais, A. D., Tanyanyiwa, D. M., & Burnett, J. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.039 · Cited by 364
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 361
Kereiakes, D. J., Robinson, J. G., Cannon, C. P., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.004 · Cited by 349
Li, H., Dong, B., Park, S. W., Lee, H.-S., Chen, W., & Liu, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052407 · Cited by 348
Maxwell, K. N., Soccio, R. E., Duncan, E. M., Sehayek, E., & Breslow, J. L. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300203-jlr200 · Cited by 329
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
Timms, K. M., Wagner, S., Samuels, M. E., Forbey, K., Goldfine, H., Jammulapati, S., Skolnick, M. H., Hopkins, P. N., Hunt, S. C., & Shattuck, D. M. (2004) · Human Genetics · doi:10.1007/s00439-003-1071-9 · Cited by 321
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Careskey, H. E., Davis, R. A., Alborn, W. E., Troutt, J. S., Cao, G., & Konrad, R. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700437-jlr200 · Cited by 313
Pirillo, A., & Catapano, A. L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.032 · Cited by 305
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
Cameron, J., Holla, Ø. L., Ranheim, T., Kulseth, M. A., Berge, K. E., & Leren, T. P. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl077 · Cited by 258 · cited 2×
“All these mutations were found in patients with high levels of blood cholesterol and presenting typical features of FH. Studies showed that the two GOF mutations, p.S127R and p.D374Y, lead to a 23% decreased level of cell surface LDLR and a 38% decreased level of internalization of LDL as compared with WT-PCSK9 [15].”
ResultLipinski, M. J., Benedetto, U., Escarcega, R. O., Biondi-Zoccai, G., Lhermusier, T., Baker, N. C., Torguson, R., Brewer, H. B., & Waksman, R. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv563 · Cited by 256 · cited 1×
“An increased incidence of neurocognitive AEs with antiPCSK9 antibodies treatment when compared with placebo [135] was observed in one meta-analysis.”
BackgroundMutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
Leren, T. (2004) · Clinical Genetics · doi:10.1111/j.0009-9163.2004.0238.x · Cited by 255
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
Dias, C. S., Shaywitz, A. J., Wasserman, S. M., Smith, B. P., Gao, B., Stolman, D. S., Crispino, C. P., Smirnakis, K. V., Emery, M. G., Colbert, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.986 · Cited by 235
Berberine decreases PCSK9 expression in HepG2 cells
Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P., & Berge, K. E. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.004 · Cited by 233
Welder, G., Zineh, I., Pacanowski, M. A., Troutt, J. S., Cao, G., & Konrad, R. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m008144 · Cited by 227
Institut National de la Santé et de la Recherche Médicale
(1976) · Gut · doi:10.1136/gut.17.8.660-e · Cited by 225
A new method for measurement of total plasma PCSK9: clinical applications
Dubuc, G., Tremblay, M., Paré, G., Jacques, H., Hamelin, J., Benjannet, S., Boulet, L., Genest, J., Bernier, L., Seidah, N. G., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m900273-jlr200 · Cited by 222
Self-citationBays, H., Gaudet, D., Weiss, R., Ruiz, J. L., Watts, G. F., Gouni-Berthold, I., Robinson, J., Zhao, J., Hanotin, C., & Donahue, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1520 · Cited by 221
Gaudet, D., Kereiakes, D. J., McKenney, J. M., Roth, E. M., Hanotin, C., Gipe, D., Du, Y., Ferrand, A.-C., Ginsberg, H. N., & Stein, E. A. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.05.060 · Cited by 210
Romagnuolo, R., Scipione, C. A., Boffa, M. B., Marcovina, S. M., Seidah, N. G., & Koschinsky, M. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.611988 · Cited by 206
Self-citationFarnier, M., Jones, P., Severance, R., Averna, M., Steinhagen-Thiessen, E., Colhoun, H. M., Du, Y., Hanotin, C., & Donahue, S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.010 · Cited by 189
Novel mutations of thePCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia
Allard, D., Amsellem, S., Abifadel, M., Trillard, M., Devillers, M., Luc, G., Krempf, M., Reznik, Y., Girardet, J.-P., Fredenrich, A., et al. (2005) · Human Mutation · doi:10.1002/humu.9383 · Cited by 187
Self-citationA Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationDong, H., Zhao, Y., Zhao, L., & Lu, F. (2013) · Planta Medica · doi:10.1055/s-0032-1328321 · Cited by 171
Ballantyne, C. M., Neutel, J., Cropp, A., Duggan, W., Wang, E. Q., Plowchalk, D., Sweeney, K., Kaila, N., Vincent, J., & Bays, H. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.02.006 · Cited by 170
Combination of simvastatin with berberine improves the lipid-lowering efficacy
Kong, W.-J., Wei, J., Zuo, Z.-Y., Wang, Y.-M., Song, D.-Q., You, X.-F., Zhao, L.-X., Pan, H.-N., & Jiang, J.-D. (2008) · Metabolism · doi:10.1016/j.metabol.2008.01.037 · Cited by 162
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression #
Labonté, P., Begley, S., Guévin, C., Asselin, M.-C., Nassoury, N., Mayer, G., Prat, A., & Seidah, N. G. (2009) · Hepatology · doi:10.1002/hep.22911 · Cited by 153
Self-citationSun, X.-M., Eden, E. R., Tosi, I., Neuwirth, C. K., Wile, D., Naoumova, R. P., & Soutar, A. K. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi128 · Cited by 150
Awan, Z., Seidah, N. G., MacFadyen, J. G., Benjannet, S., Chasman, D. I., Ridker, P. M., & Genest, J. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.172932 · Cited by 149
Self-citationMitchell, T. S., Chao, G., Sitkoff, D. F., Lo, F., Monshizadegan, H., Meyers, D. S., Low, S., Russo, K., DiBella, R. A., Denhez, F., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214221 · Cited by 149
A cholesterol-lowering VLP vaccine that targets PCSK9
Crossey, E., Amar, M. J. A., Sampson, M., Peabody, J., Schiller, J. T., Chackerian, B., & Remaley, A. T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.044 · Cited by 148
Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
Galabova, G., Brunner, S., Winsauer, G., Juno, C., Wanko, B., Mairhofer, A., Lührs, P., Schneeberger, A., von Bonin, A., Mattner, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114469 · Cited by 138
Melone, M., Wilsie, L. C., Palyha, O. C., Strack, A. M., & Rashid, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.064 · Cited by 136
Affuso, F., Ruvolo, A., Micillo, F., Saccà, L., & Fazio, S. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.05.017 · Cited by 135
Abifadel, M., Guérin, M., Benjannet, S., Rabès, J., Goff, W. L., Julia, Z., Hamelin, J., Carreau, V., Varret, M., Bruckert, É., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.04.006 · Cited by 127
Self-citationJonas, M. C., Costantini, C., & Puglielli, L. (2008) · The EMBO Reports · doi:10.1038/embor.2008.132 · Cited by 119
Hopkins, P. N., Defesche, J., Fouchier, S. W., Bruckert, E., Luc, G., Cariou, B., Sjouke, B., Leren, T. P., Harada-Shiba, M., Mabuchi, H., et al. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.115.001129 · Cited by 117
Self-citationAnnexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation
Seidah, N. G., Poirier, S., Denis, M., Parker, R., Miao, B., Mapelli, C., Prat, A., Wassef, H., Davignon, J., Hajjar, K. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041865 · Cited by 117
Self-citationActivation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
Langhi, C., Le May, C., Kourimate, S., Caron, S., Staels, B., Krempf, M., Costet, P., & Cariou, B. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.02.038 · Cited by 113
Effects of berberine on lipid profile in subjects with low cardiovascular risk
Derosa, G., D'Angelo, A., Bonaventura, A., Bianchi, L., Romano, D., & Maffioli, P. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.776037 · Cited by 112
Abifadel, M., Elbitar, S., Khoury, P. E., Ghaleb, Y., Chemaly, M., Moussalli, M.-L., Rabès, J., Varret, M., & Boileau, C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0439-8 · Cited by 111
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Familial hypercholesterolaemia in Portugal
Bourbon, M., Alves, A. C., Medeiros, A. M., Silva, S. D. R., & Soutar, A. K. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.019 · Cited by 106
van Poelgeest, E. P., Hodges, M. R., Moerland, M., Tessier, Y., Levin, A. A., Persson, R., Lindholm, M. W., Dumong Erichsen, K., Ørum, H., Cohen, A. F., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12738 · Cited by 93
Persson, L., Gälman, C., Angelin, B., & Rudling, M. (2009) · Endocrinology · doi:10.1210/en.2008-1281 · Cited by 86
Homer, V. M., Marais, A. D., Charlton, F., Laurie, A. D., Hurndell, N., Scott, R., Mangili, F., Sullivan, D. R., Barter, P. J., Rye, K.-A., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.022 · Cited by 84
Mbikay, M., Sirois, F., Simoes, S., Mayne, J., & Chrétien, M. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.08.003 · Cited by 81
Pisciotta, L., Bellocchio, A., & Bertolini, S. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-123 · Cited by 79
Kastelein, J. J. P., Nissen, S. E., Rader, D. J., Hovingh, G. K., Wang, M.-D., Shen, T., & Krueger, K. A. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv707 · Cited by 77
Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.
Davignon, J., & Dubuc, G. (2009) · PubMed Central · Cited by 72
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
Troutt, J. S., Alborn, W. E., Cao, G., & Konrad, R. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m000620 · Cited by 71
Yamamoto, T., Harada-Shiba, M., Nakatani, M., Wada, S., Yasuhara, H., Narukawa, K., Sasaki, K., Shibata, M.-A., Torigoe, H., Yamaoka, T., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.16 · Cited by 69
Postmus, I., Trompet, S., de Craen, A. J. M., Buckley, B. M., Ford, I., Stott, D. J., Sattar, N., Slagboom, P. E., Westendorp, R. G. J., & Jukema, J. W. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m033969 · Cited by 67 · cited 1×
“It has been known that PCSK9 interacts with annexin A2 [136] and resistin [137] and several studies have been conducted in liver diseases [138], obesity, Alzheimer disease [139], cognitive performance [140], cancer [141], and hepatitis [142].”
BackgroundUnderstanding PCSK9 and anti-PCSK9 therapies
McKenney, J. M. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.001 · Cited by 66
Characterization of novel mutations in the catalytic domain of the PCSK9 gene
Cameron, J., Holla, Ø. L., Laerdahl, J. K., Kulseth, M. A., Ranheim, T., Rognes, T., Berge, K. E., & Leren, T. P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01915.x · Cited by 66
Berthold, H. K., Seidah, N. G., Benjannet, S., & Gouni-Berthold, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060095 · Cited by 59
Self-citationStein, E. A., Kasichayanula, S., Turner, T. A., Kranz, T., Arumugam, U., Biernat, L., & Lee, J. (2014) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(14)61372-3 · Cited by 52
Noguchi, T., Kobayashi, J., Yagi, K., Nohara, A., Yamaaki, N., Sugihara, M., Ito, N., Oka, R., Kawashiri, M., Tada, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.012 · Cited by 49
Stairs instead of elevators at the workplace decreases PCSK 9 levels in a healthy population
Kamani, C. H., Gencer, B., Montecucco, F., Courvoisier, D., Vuilleumier, N., Meyer, P., & Mach, F. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12480 · Cited by 46 · cited 1×
“Daily physical activity is independently associated with a decrease of PCSK9 levels over time [23].”
BackgroundFolsom, A. R., Peacock, J. M., & Boerwinkle, E. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0502 · Cited by 35
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
Abifadel, M., Pakradouni, J., Collin, M., Bouma, M. E., Varret, M., Rabès, J., & Boileau, C. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.518615 · Cited by 34
Self-citationSimonen, P. P., Stenman, U., & Gylling, H. (2015) · Clinical Science · doi:10.1042/cs20150193 · Cited by 24
The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia
Chen, F., Maridakis, V., O’Neill, E. A., Hubbard, B. K., Strack, A. M., Beals, C. R., Herman, G. A., & Wong, P. (2011) · Biomarkers · doi:10.3109/1354750x.2011.561367 · Cited by 23
Koren, M. J., Roth, E. M., McKenney, J. M., Gipe, D. A., Hanotin, C., Ferrand, A.-C., Wu, R., & Dufour, R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.998987 · Cited by 22
Katsiki, N., Athyros, V. G., Mikhailidis, D. P., & Mantzoros, C. S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.04.007 · Cited by 21
Miyoshi, T., Nakamura, K., Doi, M., & Ito, H. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0119-2 · Cited by 20
Raal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R. C., Wasserman, S. M., & Stein, E. A. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.05.004 · Cited by 17
Lin, J., Wang, L., Liu, S., Wang, X.-M., Qiang, Y., Yang, Y., Lan-ping, D. U., Pan, X.-D., Wang, X., & Jiang, Z. (2010) · PubMed · Cited by 12
Tingley, W. G., Luca, D., Leabman, M. K., Budha, N. R., Kahn, R., Baruch, A., Cowan, K. J., & Davis, J. C. (2013) · Heart · doi:10.1136/heartjnl-2013-304613.423 · Cited by 4
Beyer, T. P., Eacho, P. I., Schroeder, K. M., Hansen, R. J., Wroblewski, V. J., Han, B., Pickard, R. T., & Kowala, M. C. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvb.35.suppl_1.538 · Cited by 4
(2016) · Nature Biotechnology · doi:10.1038/nbt0516-452a · Cited by 3
Cited by
Genetic and molecular architecture of familial hypercholesterolemia
Abifadel, M., & Boileau, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13577 · Cited by 176
Self-citationGenetic and microbiome influence on lipid metabolism and dyslipidemia
Matey-Hernandez, M. L., Williams, F. M. K., Potter, T., Valdes, A. M., Spector, T. D., & Menni, C. (2018) · Physiological Genomics · doi:10.1152/physiolgenomics.00053.2017 · Cited by 130
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 116
Self-citationTargeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Katzmann, J. L., Gouni-Berthold, I., & Laufs, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.595819 · Cited by 87
Metadata
- Authors
- Elbitar, S., Khoury, P. E., Ghaleb, Y., Rabès, J.-P., Varret, M., Seidah, N. G., Boileau, C., & Abifadel, M.
- Affiliations
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Montreal Clinical Research Institute (CA)
- ,
- Corresponding author
- Abifadel, Marianne
- ORCID
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2016-07-12
- Volume
- 26
- Issue
- 12
- Pages
- 1377-1392
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2466927139
- Semantic Scholar
- 23a1de473e3572cf5767b7f62869b431f0b74572
- Cited by
- 29
- References
- 120
- Citations by year
- 2024: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 7 · 2017: 5 · 2016: 4
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Therapeutic Patents (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fondation-Leducq (FLQ # 13 CVD 03)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9 inhibitors, PCSK9, anti-PCSK9 monoclonal antibodies, alirocumab, evolocumab, LDL cholesterol lowering, lipid-lowering drugs, PCSK9 mutations, cardiovascular outcomes, patent analysis
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Animals, Antibodies, Monoclonal, Anticholesteremic Agents, Humans, Cholesterol, LDL, Mutation, Patents as Topic, Drug Design, Dyslipidemias, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.